公开(公告)号：EP1670893A2

公开(公告)日：2006-06-21

申请号：EP04782469.3

申请日：2004-08-27

申请人： THE IMMUNE RESPONSE CORPORATION

发明人： MOSS, Ronald, B.

IPC分类号： C12N1/00

CPC分类号： A61K39/21 ,  A61K39/00 ,  A61K39/12 ,  A61K2039/5252 ,  A61K2039/5254 ,  A61K2039/545 ,  A61K2039/55 ,  A61K2039/555 ,  A61K2039/55561 ,  A61K2039/55566 ,  A61K2039/57 ,  A61K2039/62 ,  A61K2039/627 ,  C07K14/005 ,  C12N2740/16222 ,  C12N2740/16234

摘要： The invention provides immunogenic compositions which enhance the duration and strength of the immune response in a mammal. The immunogenic compositions contain an HIV antigen, an immunomer and an adjuvant. The HIV antigen can be a whole-killed HIV virus devoid of outer envelope protein gp120. Alternatively, the HIV antigen can be a whole-killed HIV virus, or a p24 antigen. Also provided are kits, the components of which, when combined, produce the immunogenic compositions of the invention. The invention also provides methods of making the immunogenic compositions, by combining an HIV antigen, an immunomer and optionally an adjuvant. The invention further provides a method of immunizing a mammal, by enhancing an immune response in the mammal by administering to the mammal an immunogenic composition containing an HIV antigen, an immunomer and optionally an adjuvant. Also provided is a method of inhibiting in a mammal by administering to the mammal an immunogenic composition containing an HIV antigen, an immunomer and optionally an adjuvant.

公开(公告)号：EP0738281B1

公开(公告)日：2002-11-13

申请号：EP95909258.6

申请日：1995-01-13

申请人： THE IMMUNE RESPONSE CORPORATION

发明人： CHANG, Jennie, C., C. ,  BROSTOFF, Steven, W. ,  CARLO, Dennis, J.

IPC分类号： C07K14/725 ,  A61K38/17 ,  G01N33/68 ,  A61P17/06

CPC分类号： A61K39/0008 ,  A61K38/00 ,  A61K39/00 ,  A61K48/00 ,  A61K2039/53 ,  C07K14/7051 ,  C07K16/2809 ,  C07K16/4258 ,  G01N33/56972 ,  G01N2800/285

摘要： This invention relates to methods of preventing or reducing the severity of psoriasis. In one embodiment, the method involves administering to the individual a peptide having substantially the sequence of a non-conserved region sequence of a T cell receptor present on the surface of T cells mediating psoriasis or a fragment thereof, wherein the peptide or fragment is capable of causing an effect on the immune system to regulate the T cells. In particular, the T cell receptor has the Vβ region Vβ3, Vβ13.1 or Vβ17. In another embodiment, the method involves gene therapy. The invention also relates to methods of diagnosing psoriasis by determining the presence of psoriasis predominant T cell receptors.

公开(公告)号：EP0584279B1

公开(公告)日：2001-03-14

申请号：EP92913964.0

申请日：1992-05-14

申请人： THE UNIVERSITY OF CONNECTICUT ,  THE IMMUNE RESPONSE CORPORATION

发明人： WU, George, Y. ,  SPITALNY, George, L. ,  FINDEIS, Mark, A.

IPC分类号： A61K47/48

CPC分类号： C12N15/87 ,  A61K39/12 ,  A61K39/292 ,  A61K47/645 ,  A61K48/00 ,  A61K2039/53 ,  A61K2039/6093 ,  C07K16/00 ,  C07K16/082 ,  C12N2730/10134

摘要： Molecular complexes can be used to target a gene encoding an immunogenic protein or polypeptide to a specific cell in vivo. The gene is incorporated into the target cell, expressed and the gene-encoded product is secreted and an immune response against the immunogenic protein or polypeptide is elicited. The molecular complex comprises an expressible gene encoding a desired immunogenic protein or polypeptide complexed with a carrier of a cell-specific binding agent and a gene-binding agent. The cell-specific binding agent is specific for a cellular surface structure which mediates internalization of ligands by endocytosis. An example is the asialoglycoprotein receptor of hepatocytes. The gene-binding agent is a compound such as a polycation which stably complexes the gene under extracellular conditions and releases the gene under intracellular conditions so that it can function within a cell. The molecular complex is stable and soluble in physiological fluids and can be used to elicit an immune response against a variety of immunogens in an organism for the purpose of vaccination or for the production of antibodies.

公开(公告)号：EP1036177A1

公开(公告)日：2000-09-20

申请号：EP98960546.4

申请日：1998-11-25

申请人： THE IMMUNE RESPONSE CORPORATION

发明人： ILL, Charles, R. ,  GONZALES, Jose, E., N. ,  YANG, Claire, Q. ,  BIDLINGMAIER, Scott

IPC分类号： C12N15/12 ,  C12N15/67 ,  C12N15/85 ,  C07K14/755 ,  A61K48/00

CPC分类号： C07K14/755 ,  A61K48/00 ,  C12N15/67 ,  C12N15/85 ,  C12N2830/008 ,  C12N2830/30 ,  C12N2830/42 ,  C12N2830/48 ,  C12N2830/85 ,  C12N2840/44 ,  C12N2840/445

摘要： Novel genes and vectors exhibiting increased expression and novel splicing patterns are disclosed. The gene can comprise one or more consensus or near consensus splice sites which have been corrected. The gene can alternatively or additionally comprise one or more introns within coding or noncoding sequences. The gene can still further comprise modified 5' and/or 3' untranslated regions optimized to provide high levels and duration of tissue-specific expression. In one embodiment, the gene comprises the coding region of a full-length Factor VIII gene modified by adding an intron within the portion of the gene encoding the β-domain, so that the gene is expressed as a β-domain deleted Factor VIII protein. The novel Factor VIII gene can also be modified to correct one or more consensus or near consensus splice sites within or outside of the coding region.

公开(公告)号：EP0751988B1

公开(公告)日：2000-02-09

申请号：EP95914170.6

申请日：1995-03-22

申请人： THE IMMUNE RESPONSE CORPORATION

发明人： PRIOR, Christopher, P. ,  WEBER, David, M. ,  GORE, Richard, S. ,  HARTER, James, J. ,  HRINDA, Michael, E. ,  MITSCHELEN, Jonathan, J. ,  IRISH, Thomas, W. ,  BAY, Pierre, M. ,  TARR, George, C.

IPC分类号： C12N7/02 ,  C12N5/02

CPC分类号： C12N7/00 ,  C07K14/005 ,  C12N2740/16022 ,  C12N2740/16051 ,  C12N2740/16122

公开(公告)号：EP0568623A1

公开(公告)日：1993-11-10

申请号：EP92904843.0

申请日：1992-01-21

申请人： THE IMMUNE RESPONSE CORPORATION

发明人： HOWELL, Mark, D. ,  BROSTOFF, Steven, W. ,  CARLO, Dennis, J.

IPC分类号： A61K39 ,  A61K38 ,  A61P25 ,  A61P29 ,  A61P37 ,  C07K7 ,  C07K14 ,  C07K16 ,  C12N15 ,  C12Q1 ,  A61K48

CPC分类号： C07K16/2809 ,  A61K39/00 ,  A61K48/00 ,  A61K2039/53 ,  C07K14/7051 ,  C07K16/4258

摘要： L'invention décrit des vaccins et un moyen de vaccination d'un vertébré, afin de prévenir ou de réguler des pathologies spécifiques provoquées par les lymphocytes T, y-compris des maladies autoimmunes et la réplication démesurée des lymphocytes T. Le vaccin se compose d'un récepteur de lymphocyte T (TCR) ou d'un fragment dudit vaccin correspondant à un TCR présent sur la surface des lymphocytes T à l'origine de la pathologie. Le fragment du vaccin peut être un peptide correspondant à des séquences de TCR caractéristiques des lymphocytes T à l'origine de ladite pathologie. Ledit peptide peut se lier à des antigènes classiques combinés pour former des cellules de présentation d'un antigène du complexe majeur d'histocompatibilité (CMH) ou des superantigènes. L'invention décrit également des moyens de détermination de séquences d'aminoacides appropriées correspondant auxdits vaccins. Le vaccin s'administre au vertébré de façon à provoquer une réaction immune dirigée contre le TCR des lymphocytes T à l'origine de la pathologie. Cette réaction immune réduit ou supprime les lymphocytes T papathogènes, anihilant ainsi la pathogénèse de la maladie. L'invention décrit, de plus, des régions variables à chaîne beta spécifique des récepteurs de lymphocytes T, désignées Vbeta3, Vbeta4, Vbeta12, Vbeta14 et Vbeta17, , associées à la pathogénèse de maladies autoimmunes telles que l'arthrite rhumatoïde (RA) et des scléroses multiples (MS). Sont également décrits des moyens de détection, de prévention et de traitement de RA et MS. Sont également décrits des moyens d'administration de l'ADN ou de l'ARN codant les polypeptides s'utilisant en tant que vaccins objets de l'invention, dans les cellules tissulaires d'un individu.

公开(公告)号：EP1355663A1

公开(公告)日：2003-10-29

申请号：EP02705944.3

申请日：2002-01-24

申请人： THE IMMUNE RESPONSE CORPORATION

发明人： MOSS, Ronald, B. ,  CARLO, Dennis, J.

IPC分类号： A61K39/21 ,  A61P31/18

CPC分类号： A61K39/21 ,  A61K39/12 ,  A61K2039/545 ,  A61K2039/57 ,  C12N2740/16034 ,  A61K2300/00

摘要： The invention provides a method for the treatment of HIV infected individuals. The method is practiced by combining immunization with an HIV immunogenic composition with structured cycles of anti-retroviral treatment and withdrawal from treatment.

公开(公告)号：EP0904373A1

公开(公告)日：1999-03-31

申请号：EP97915916.0

申请日：1997-03-14

申请人： THE IMMUNE RESPONSE CORPORATION

发明人： CHIOU, Henry, C. ,  CARLO, Dennis, J.

IPC分类号： C12N15 ,  A61K31 ,  A61K35 ,  A61K38 ,  A61K45 ,  A61K47 ,  A61K48 ,  A61P43

CPC分类号： C12N15/87 ,  A61K38/212 ,  A61K47/645 ,  A61K48/00 ,  A61K48/0058 ,  A61K48/0066

摘要： A molecular complex comprising a gene encoding interferon releasably linked to a conjugate of a nucleic acid binding agent and a ligand which binds to a component on the surface of a cell. In a preferred enbodiment, the gene encodes human IFN-α, IFN-β, or IFN-η. The complex can be used to obtain targeted expression of interferon in selected cells either in vivo or in vitro.

公开(公告)号：EP0831881A1

公开(公告)日：1998-04-01

申请号：EP96918201.0

申请日：1996-06-05

申请人： THE IMMUNE RESPONSE CORPORATION

发明人： KWOH, Deborah, Y. ,  BROSTOFF, Steven, W. ,  CARLO, Dennis, J.

IPC分类号： A61K38 ,  A61P3 ,  A61P9 ,  C07K14 ,  A61K39

CPC分类号： C07K14/47 ,  A61K39/00

摘要： The present invention provides a method for increasing HDL cholesterol in a mammal by stimulating an immune response that inhibits the function of CETP. Such an immune response can be induced by immunizing with CETP or fragments of CETP (together termed 'CETP Peptides') which contain an epitope capable of stimulating such a response. The peptides can be conjugated to a carrier, such as KLH or ovalbumin, in order to increase immunogenicity. Adjuvants can also be administered.

公开(公告)号：EP0685236A1

公开(公告)日：1995-12-06

申请号：EP95250152.6

申请日：1988-06-09

申请人： THE IMMUNE RESPONSE CORPORATION, INC.

发明人： Salk, Jonas ,  Carlo, Dennis J.

IPC分类号： A61K39/21 ,  C07K16/10

CPC分类号： C07K14/005 ,  A61M1/3687 ,  C12N2740/16122

摘要： The present invention provides a non-infectious immunogen containing retroviral particles devoid of outer envelope proteins or containing selected antigens isolated from a retrovirus. There is also provided a vaccine effective against HIV. In one aspect, the immunogen is useful for immunizing an individual previously infected by a retrovirus including HIV, so as to induce immunoprotective factors protective against progression of the infection. In another aspect, the vaccine is useful for vaccinating an individual not previously infected with HIV in order to prevent subsequently acquired infection. In another aspect, there is provided a method of rendering a viral immunogen non-infectious. The immunogen may also be used to produce antibodies for passive immunotherapy, alone or in conjunction with active immunotherapy, in individuals infected with a retrovirus, including HIV, preferably those individuals exhibiting low levels of antibodies to retroviral gene products other than the outer envelope.

摘要翻译： 本发明提供了可用于体外从HIV个体除去gp160 / 120的抗体的组合物，其包含与gp160 / 120反应的附属配体的基质，使得gp160 / 120的抗体将结合到所述基质以及 抗独特型抗体与抗gp160 / 120抗体反应。